AA. [20] [21] [22] [23] Therefore, the possibility arises that cPLA 2 α, which is highly selective in releasing AA, might function as the major center of convergence for the transduction of hormone signaling to eicosanoid production and regulation of BP.
PLA 2 activity is increased in the renal medulla and cortex of stroke-prone spontaneously hypertensive rats, 24 and a recent study showed the involvement of cPLA 2 α in l-NG-nitroarginine methyl ester, an inhibitor of NO synthesis-induced hypertension. 25 However, the contribution of cPLA 2 α to other forms of hypertension and more importantly its significance in cardiovascular remodeling and dysfunction, oxidative stress, and inflammation in Ang II-induced hypertension and the underlying mechanism is not known and is the major objective of this study. These results show that cPLA 2 α is crucial for the development of Ang II-induced hypertension and associated cardiovascular dysfunction, oxidative stress, inflammation and remodeling, most likely because of the effect of predominantly prohypertensive eicosanoids generated from AA released by this lipase.
Methods
The detailed experimental methods are described in the online-only Data Supplement.
Results cPLA 2 α Contributes to the Development of Ang II-Induced Hypertension and Activation of Cardiac cPLA 2 in Mice
Ang II infusion over a period of 13 days produced a consistent and reproducible increase in systolic BP, measured by the tail cuff ( Figure 1A ). Systolic ( Figure 1B ), diastolic ( Figure 1C ), and mean arterial BP ( Figure 1D ) were measured by radio telemetry ( Figure S1 in the online-only Data Supplement: tracing from all experiments) in cPLA 2 α +/+ but not cPLA 2 α −/− mice. Basal BP was not different between these 2 phenotypes.
Tracings of the BP measured by radio telemetry for each individual cPLA 2 α +/+ and cPLA 2 α −/− mouse during Ang II infusion is shown in Figure S1 -A1 and S1-A2. Heart rate during Ang II infusion as measured by radio telemetry was not altered in cPLA 2 α +/+ or cPLA 2 α −/− mice ( Figure S1B ). Power spectral analysis of BP and heart rate variability showed an increase in the ratio of low frequency:high frequency heart rate variability during Ang II infusion in cPLA 2 α +/+ mice, indicating increased sympathetic outflow. This ratio was decreased in cPLA 2 α −/− mice ( Figure S1C ). Ang II also resulted in increased cPLA 2 activity measured by its phosphorylation, but not its protein expression, in cardiac tissue of Ang II-infused cPLA 2 α +/+ mice; the expression of cPLA 2 protein was absent in cPLA 2 α −/− mice ( Figure S1D ).
Arachidonic Acid Metabolism Mediates Ang II-Induced Hypertension in cPLA 2 α +/+ Mice
To elucidate the mechanism by which Ang II mediates hypertension in WT mice, another group of cPLA 2 α +/+ mice were infused with Ang II and concurrently injected with an inhibitor of AA metabolism, 5,8,11,14 eicosatetraynoic acid, at a dose of 50 mg/kg, IP every third day. 5, 8, 11, 14 Eicosatetraynoic acid prevented Ang II-induced increase in systolic BP in cPLA 2 α +/+ mice ( Figure S2 ). mice were infused with either Ang II (700 ng/kg/min) or its vehicle (0.9% saline) with micro-osmotic pumps for 13 days, and systolic blood pressure was measured by tail cuff (A) and radio telemetry (B). Diastolic blood pressure (C) and mean arterial pressure (D) were also measured by telemetry. *P<0.05 cPLA 2 α +/+ vehicle vs cPLA 2 α +/+ Ang II, #P<0.05 cPLA 2 α +/+ Ang II vs cPLA 2 α −/− Ang II (n=4-6 for all experiments, and data are expressed as mean±SEM, data were analyzed by RM 2-way analysis of variance followed by Turkey's multiple comparison tests).
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Ang II infusion resulted in a significant increase in urinary excretion of PGE2 metabolites (PGEM; 13,14-dihydro-15-keto PGA2, 13,14-dihydro-15-keto PGE2; Figure The possibility arises that disrupting cPLA 2 α may alter the expression of other related phospholipases. Thus, we performed q-RT PCR analysis for various phospholipases. mRNA expression of cPLA 2 α, but not other related enzymes, was absent in cardiac tissue of cPLA 2 α −/− mice ( Figure S3A ). Cardiac protein expression of phospholipase Cβ2, D1, and D2 was neither affected by cPLA 2 α disruption or Ang II infusion in either of the treatment groups ( Figure S3B ). To determine whether decreased BP during Ang II infusion in cPLA 2 α −/− mice results from alterations in expression of Ang II type 1 (AT1) and 2 (AT2), Ang (1-7) Mas receptor, or angiotensin converting enzyme (ACE), we measured cardiac expression of these receptors and ACE. Expression of AT1, AT2, Mas receptor, and ACE were not altered in cardiac tissue of cPLA 2 α −/− mice ( Figure S3C ).
cPLA 2 α Gene Disruption Prevents Cardiac Dysfunction and Fibrosis Associated With Ang II-Induced Hypertension in Mice
Cardiac functional and structural changes were measured by echocardiography on the 12th day of infusion of Ang II or its vehicle. M-mode images of the left ventricle (LV) in the parasternal long-axis view showed dilated cardiomyopathy as indicated by LV chamber enlargement and impaired contractility in Ang II-infused cPLA 2 α +/+ but not cPLA 2 α −/− mice ( Figure 3A ). Various parameters (Table) revealed cardiac dysfunction, including an increase in LV mass in Ang II-infused cPLA 2 α +/+ but not cPLA 2 α −/− mice. Heart sections of Ang IIinfused cPLA 2 α +/+ but not cPLA 2 α −/− mice showed fibrosis as indicated by positive staining of intracardiac α-smooth muscle actin (α-SMA) ( Figure 3B ), transforming growth factor-β ( Figure 3C ), and collagen ( Figure 3D ).
cPLA 2 α Gene Disruption Prevents Cardiac Inflammation
To determine the contribution of cPLA 2 α to inflammation associated with Ang II-induced hypertension, we examined the localization of F4/80 + macrophages and CD3 + T-lymphocytes in cardiac tissue of cPLA 2 α +/+ and cPLA 2 α −/− mice. Ang II caused infiltration of F4/80 + macrophages ( Figure S4A ) and CD3 + T cells ( Figure S4B ) in the hearts of cPLA 2 α +/+ but not cPLA 2 α −/− mice.
cPLA 2 α Gene Disruption Protects Against Ang II-Induced Vascular Remodeling
To assess the effect of cPLA 2 α gene disruption on vascular remodeling associated with Ang II-induced hypertension, aortas were stained with hematoxylin and eosin, and media:lumen ratio was calculated. The aortas were also stained for α-SMA and collagen. Ang II increased media:lumen ratio ( Figure 4A ), α-SMA ( Figure 4B ) positive stained cells, and collagen accumulation ( Figure 4C ) in aortas of cPLA 2 α +/+ mice compared with cPLA 2 α −/− mice.
cPLA 2 α Gene Disruption Prevents Increased Vascular Reactivity and Endothelial Dysfunction in Ang II-Induced Hypertension
Ang II-induced hypertension was associated with increased response of aortas to phenylephrine ( Figure S5A ) and endothelin-1 ( Figure S5B ) in cPLA 2 α +/+ mice; these increases were abrogated in cPLA 2 α −/− mice. Ang II infusion caused endothelial dysfunction, as indicated by diminished dilation to acetylcholine in aortas preconstricted with phenylephrine in cPLA 2 α +/+ but not cPLA 2 α −/− mice ( Figure S5C ). Endothelialindependent relaxation of aorta to sodium nitroprusside was not altered ( Figure S5D ).
cPLA 2 α Gene Disruption Protects Against Ang II-Induced Cardiovascular Oxidative Stress
Oxidative stress has been implicated in various models of hypertension, including Ang-II, 11, 26 and Ang II-induced activation of cardiac nicotinamide adenine dinucleotide phosphate (NADPH) oxidase depends on PLA 2 activity in vascular smooth muscle cells in vitro. Therefore, we investigated whether cPLA 2 gene disruption prevents Ang II-induced oxidative stress in heart and aorta. NADPH oxidase activity, measured by lucigenin-based luminescence assay, was increased Figure S6A ). Infusion of Ang II increased cardiac ( Figure S6B and S6C) and aortic ( Figure S6D and S6E) ROS production in cPLA 2 α +/+ but not in cPLA 2 α −/− mice measured by fluorescence of 2-hydroxyethidium generated after exposure of cardiac tissue and aorta to dihydroethidium.
cPLA 2 α Gene Disruption Prevents Endoplasmic Reticulum Stress in Ang II-Induced Hypertension
Endoplasmic reticulum (ER) stress has been implicated in Ang II-induced hypertension. 27 To determine whether Ang II infusion promotes ER stress in the heart and whether it is dependent on cPLA 2 α, we measured mRNA expression of ER stress biomarkers p58 IPK , GRP78, XBP, and CHOP (GADD153). Ang II infusion increased cardiac mRNA expression of p58
IPK that is induced in the early adaptive phase of the unfolded protein response and CHOP (GADD153), a chronic ER stress marker 28 It is well established that, in vascular smooth muscle cells, Ang II increases the production of ROS and activity of ≥1 signaling molecules, including extracellular signalregulated kinase (ERK1/2) and cSrc that contributes to hypertrophy. 29 ERK1/2 also promotes phosphorylation of cPLA 2 . 30 Ang II infusion increased ERK1/2 ( Figure S8A ) and cSrc ( Figure S8B ) activity as measured by phosphorylation of these kinases in the heart tissue of cPLA 2 α +/+ but not in cPLA 2 α −/− mice. (Table) . Increased interstitial staining of α-smooth muscle actin (α-SMA; B) and transforming growth factor (TGF)-β (C) indicators of interstitial fibrosis and collagen accumulation (D; intense blue staining) was observed in Ang II-infused cPLA 2 α +/+ but not cPLA 2 α −/− mice (n=4-6 for each group; data are expressed as mean±SEM). 
Discussion
The novel finding of this study is the demonstration that cPLA 2 α is crucial for the development of Ang II-induced hypertension and associated cardiovascular dysfunction and hypertrophy, cardiac fibrosis, inflammation, oxidative stress, and activation of ERK1/2 and cSrc in mice. This conclusion is based on our finding that infusion of Ang II increased systolic BP, measured by tail cuff as well as radio telemetry, in cPLA 2 α +/+ mice that was minimized by cPLA 2 α gene disruption. The selectivity of this effect of cPLA 2 α gene disruption in our mice was indicated by loss of cardiac expression of its mRNA but not that of other related phospholipase enzymes. The protein expression of PLA 2 but not PLCβ2, PLD1, or PLD2 was also absent in cPLA 2 α −/− mice. Because cPLA 2 α selectively catalyzes release of AA from tissue lipids 12 and Ang II is known to activate cPLA 2 to release AA, cPLA 2 seems to mediate the hypertensive effect of Ang II via AA release. Supporting this view was our finding that cPLA 2 activity, as indicated by its phosphorylation, was increased in the heart of cPLA 2 α +/+ but not cPLA 2 α −/− mice. The induction of eicosanoid production by lipopolysaccharide and calcium ionophore A23187 in peritoneal macrophages and furosemide-induced PGE2 excretion was also abolished in cPLA 2 α −/− mice. 16, 31, 32 In the present study, Ang II infusion increased the urinary output of PGEM, TXB2, 20-HETEs in cPLA 2 α +/+ but not cPLA 2 α −/− mice. Moreover, administration of inhibitor of AA metabolism, 5,8,11,14 eicosatetraynoic acid, blocked Ang II-induced increase in systolic BP in cPLA 2 α +/+ mice. Therefore, it seems that metabolites of AA with prohypertensive effects contribute to the development of hypertension caused by Ang II in these mice. Because cPLA 2 α gene disruption or 5,8,11,14 eicosatetraynoic acid did not alter basal BP, it seems that cPLA 2 α activation and release of AA and its metabolites are not required to maintain basal BP.
The increase in BP produced by Ang II in cPLA 2 α +/+ mice that was associated with cardiac dysfunction as indicated by decreased ejection fraction, fractional shortening, cardiac output, increased end diastolic volume and end systolic volume, and cardiac hypertrophy as shown by increased LV mass Ang II indicates angiotensin II; CO, cardiac output (mL/min); d, diastole; EDV, end diastolic volume (μL); EF, ejection fraction; ESV, end systolic volume; FS, fractional shortening; IVS, intraventricular septum (mm); LVAW, LV anterior wall (mm); LVID, LV internal dimension (mm); LV mass, left ventricular mass (mgs); LVPW, LV posterior wall (mm); s, systole; and SV, stroke volume (μL).
The parameters listed in the table were measured using M-mode and B-mode images in the short and parasternal long-axis views as described in the methods. were minimized in cPLA 2 α −/− mice, suggesting an essential role of cPLA 2 α +/+ in cardiac dysfunction and hypertrophy. Moreover, in the present study, cardiac fibrosis and inflammation as indicated by increased intracardiac staining of α-SMA myofibroblasts, transforming growth factor-β, and by increased infiltration of F4/80 + and CD3 + cells in Ang II-infused cPLA 2 α +/+ mice were prevented in cPLA 2 α −/− mice. These findings suggest that AA metabolites with prohypertensive effects also mediate cardiac fibrosis and inflammation associated with Ang II-induced hypertension. cPLA 2 α was also found to be critical for increased vascular remodeling and reactivity associated with Ang II-induced hypertension characterized by an increase in various parameters, such as media:lumen ratio, α-SMA, deposition of collagen, as well as by increased contractile response of aorta to phenylephrine and endothelin-1 in cPLA 2 α +/+ but not cPLA 2 α −/− mice. Although the effect of Ang II on cardiovascular remodeling has been shown to be independent of an increase in BP, [33] [34] [35] [36] we cannot exclude the possibility that the protection against Ang II-induced cardiovascular remodeling in cPLA 2 α −/− mice could also be caused by decreased BP. The precise mechanism by which increase in BP causes cardiovascular remodeling is not known. Because stretch can increase cPLA 2 activity and eicosanoid production, 37 it raises the possibility that the increased stretch associated with hypertension might also result in cPLA 2 α activation and generation of eicosanoids that contribute to Ang II-induced cardiovascular remodeling. Ang II-induced hypertension is also known to be associated with endothelial dysfunction. 26 Our finding that Ang II-induced endothelial dysfunction, as indicated by diminished relaxation of aorta to acetylcholine but not to sodium nitroprusside, an agent that acts directly on vascular smooth muscle cells, occurs selectively in cPLA 2 α +/+ but not cPLA 2 α −/− mice suggests that cPLA 2 α is essential for endothelial dysfunction associated with Ang II-induced hypertension. Moreover, endothelial dysfunction in larger vessels is dependent on NO. 38 Hypertension caused by the inhibitor of NO synthesis, l-NG-nitroarginine methyl ester, which has been attributed to increased activity of renin-angiotensin system and sympathetic nervous systems, 39, 40 is also associated with endothelial dysfunction in the aorta. Both hypertension and endothelial dysfunction are prevented in cPLA 2 α −/− mice. 25 The mechanism by which cPLA 2 α gene disruption protects against Ang II-induced hypertension and cardiovascular remodeling, inflammation, increased vascular reactivity, and endothelial dysfunction could be caused by alterations in expression of Ang II, Ang (1-7) receptors, and ACE. However, this possibility seems to be unlikely because the expression levels of AT1, AT2, Mas receptor, and ACE examined in the heart were not different in cPLA 2 α −/− compared with cPLA 2 α +/+ mice. Oxidative stress and activation of immune system have been implicated in various models of hypertension, including Ang II-induced hypertension. 41, 42 In the present study, Ang II-induced hypertension was associated with increased oxidative stress, as shown by increased cardiac NADPH oxidase activity and ROS production in the heart and aorta and cardiac infiltration of F4/80 + macrophages and CD3 + T lymphocytes in cPLA 2 α +/+ mice. These changes were prevented in cPLA 2 α −/− mice, suggesting that increased oxidative stress and inflammation in Ang II-induced hypertension are dependent on cPLA 2 α. Supporting this view, it has been shown that Ang II increases NADPH oxidase activity by activating cPLA 2 and release of AA in vascular smooth muscle cells. 43, 44 cPLA 2 α-generated AA has also been implicated in NADPH oxidase activation in human monocytes and myeloid cell line PLB-985. 45, 46 AA metabolites generated by COX, PGE2 via its actions on EP1 and EP3 receptors, 47, 48 and TXA2 49 contributes to Ang II-induced hypertension. AA metabolites formed by 12/15 lipoxygenase 9,50 and by CYP450 4A (20-HETE), 51, 52 also contribute to Ang II-induced hypertension. Therefore, protection against Ang II-induced hypertension and associated cardiovascular pathogenesis in cPLA 2 α −/− mice is most likely caused by lack of AA release and generation of ≥1 metabolites that mediate hypertensive effects of Ang II. Supporting this conclusion was our finding that Ang II infusion increased the urinary excretion of PGEM, TXB2, and 20-HETE in cPLA 2 α +/+ but not in cPLA 2 α −/− mice. The site of prohypertensive eicosanoids generated by cPLA 2 α that participate in Ang II-induced hypertension is not known. Because cPLA 2 α is ubiquitously distributed in various tissues and eicosanoids generated from AA act locally, it is possible that eicosanoids generated at the site of action of Ang II, including the cardiovascular, renal, brain, and immune cells, could contribute to Ang II-induced hypertension. Recently, it has been shown that Ang II by stimulating expression of (pro)renin receptor in the rat renal medulla through COX2-generated PGE2, via stimulation of EP4 receptors, increases renin release that partly contributes to Ang II-induced hypertension. 53 Also mice lacking macrophage 12/15 lipoxygenase have been shown to be resistant to l-NG-nitroarginine methyl ester or deoxycorticosterone salt-induced hypertension. 54 Ang II is known to cause hypertension by increasing oxidative stress in subfornical organ of circumventricular organs and via its projections to paraventricular nucleus and from there to the brain stem, finally resulting in increased sympathetic activity. 55 cPLA 2 α is also present in the brain 13, 16 and intracerebroventricular administration of PGE2 increases sympathetic nervous activity, vasopressin release, and BP. 56 The demonstration that the effect of Ang II in increasing BP is mediated by activation of the EP1 receptor by PGE2, formed by COX-1 and not COX-2 in subfornical organ, most likely by release of AA, suggests involvement of cPLA 2. 57 Therefore, it is possible that Ang II-induced hypertension in our study could be mediated by activation of cPLA 2 α in the subfornical organ, as well as in the cardiovascular and renal systems. Moreover, it has been reported that Ang II salt hypertension, which is associated with increased sympathetic activity and increased plasma levels of norepinephrine, is minimized by inhibitor of COX-1, SC560, but not nemsulide, an inhibitor of COX-2, suggesting that COX-1-derived prostanoids by activating sympathetic nervous system increase BP. 58 In contrast, COX-2 inhibitors rofecoxib and nimesulide have been shown to attenuate Ang II-induced oxidative stress, hypertension, and cardiac hypertrophy in rats. 59 The reason for the discrepancy between the 2 studies is unknown. Ang II is known to cause modulation of sympathetic outflow as determined by power spectral analysis of BP and heart rate variability. 60 Our demonstration that the ratio of low frequency:high frequency heart rate variability as determined by power spectral analysis that was increased in cPLA 2 α +/+ mice was reduced in cPLA 2 α −/− mice suggests that AA metabolites also contributes to modulation of sympathetic outflow by Ang II.
The oxidative stress produced by Ang II in subfornical organ is mediated by ER stress, and inhibitors of ER stress minimize Ang II-induced hypertension. 27 Activation of cPLA 2 is associated with increased ER stress. 61 Inhibitors of ER stress reduce BP in spontaneously hypertensive rats and the effect of endothelial-derived contractile factors by suppressing H 2 O 2 production and expression of COX-1, ERK1/2, and cPLA 2 phosphorylation. 62 However, our demonstration that cPLA 2 α gene disruption prevented the cardiac expression of ER stress markers p58
IPK and CHOP suggests that Ang II also increases ER stress in the heart, but cPLA 2 α acts upstream of ER stress and NADPH oxidase activity, most likely by generating AA/ metabolites. The effect of vasoactive agents, including Ang II, to promote influx of calcium and translocation of cPLA 2 α to the nuclear envelope/ER, 63 the site of AA metabolizing enzymes (COX, lipoxygenase, and CYP P450), [64] [65] [66] raises the possibility that cPLA 2 α via AA release and its metabolism by these enzymes might regulate generation of ER stress and ROS production. In support of this view, 12/15-lipoxygenase has been implicated in ER stress in adipocytes, pancreatic islets, and rat liver. 65 The increased ROS generated by Ang II promotes cardiovascular remodeling by activating ≥1 signaling molecules. 29 Our finding that Ang II-induced hypertension was associated with increased cardiac ERK1/2 and cSrc activity in cPLA 2 α +/+ but not in cPLA 2 α −/− mice suggests that these signaling molecules are most likely activated by oxidative stress produced by cPLA 2 α-generated AA metabolites, thus contributing to cardiovascular remodeling.
In conclusion, the present study provides the first evidence that the selective release of AA by cPLA 2 α is crucial for the development of Ang II-induced hypertension and associated cardiovascular pathophysiological changes, including cardiovascular remodeling, increased vascular reactivity, endothelial dysfunction, and cardiac inflammation. These effects are most likely mediated by oxidative 11, 26, 29 and ER stress 27,62 generated by AA metabolism 65 and predominantly by prohypertensive eicosanoids, resulting in activation of ≥1 signaling molecules, including ERK1/2 and cSrc. However, studies using tissuespecific knockout of cPLA 2 α and AA metabolizing enzymes would allow further assessment of their relative contribution in various tissues to Ang II and other models of hypertension and associated pathogenesis.
Perspectives
The present study, using cPLA 2 α +/+ and cPLA 2 α −/− mice, demonstrates that cPLA 2 α selectively promotes release of AA from tissue phospholipids, a process that is critical for the development of Ang II-induced hypertension and associated cardiovascular remodeling and dysfunction, ER and oxidative stress, and inflammation. Moreover, our study suggests that cPLA 2 α might function as the major center of convergence for the transduction of hormone signaling and that endogenously released AA results in the production of eicosanoids that predominantly favor prohypertensive mechanisms, including oxidative and ER stress and inflammation. Therefore, the development of water-soluble selective inhibitors of cPLA 2 α activity would allow assessing further its contribution in cardiovascular and renal dysfunction in hypertension and its associated pathogenesis and treatment.
• Cardiac oxidative and endoplasmic reticulum stress and inflammation associated with Ang II-induced hypertension also depends on cPLA 2 α.
• Ang II-induced cardiac dysfunction, remodeling, and inflammation that depend on cPLA 2 α are most likely mediated by ERK1/2 and cSrc.
What Is Relevant?
• Our study provides novel information on the mechanism of Ang II-induced hypertension and associated cardiovascular pathophysiological changes, whereby cPLA 2 α-generated arachidonic acid and its metabolism to eicosanoids with prohypertensive effects is crucial for Ang IIinduced hypertension.
• These findings suggest that development of agents that selectively inhibit cPLA 2 α activity could be useful in treating hypertension and its pathogenesis.
Summary
The present study demonstrates that cPLA 2 α gene disruption and arachidonic acid metabolism inhibitor 5,8,11,14 eicosatetraynoic acid minimize Ang II-induced hypertension. Ang II-induced increase in systolic blood pressure that was associated with increased urinary excretion of eicosanoids, cardiac dysfunction studied by echocardiography, cardiovascular remodeling, increased vascular reactivity, and endothelial dysfunction in cPLA 2 α +/+ mice was markedly reduced in cPLA 2 α −/− mice. Infusion of Ang II also increased cardiac infiltration of inflammatory cells, nicotinamide adenine dinucleotide phosphate oxidase activity, and cardiovascular oxidative stress and expression of endoplasmic reticulum stress markers in cPLA 2 α +/+ but not cPLA 2 α −/− mice. Ang II increased cardiac ERK1/2 and cSrc activity in cPLA 2 α +/+ but not cPLA 2 α −/− mice. We conclude that cPLA 2 α is critical for Ang II-induced hypertension and associated cardiovascular dysfunction, remodeling, oxidative stress, and inflammation, most likely via arachidonic acid release and generation of eicosanoids with prohypertensive effects and activation of ERK1/2 and cSrc.
Methods
Animals
Experiments were performed according to protocols approved by our Institutional Animal Care and Use Committee in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals. cPLA 2 α -/-mice on a BALB/c background were generated as described 1 and provided by Dr. Joseph V. Bonventre at Brigham and Women's Hospital, Boston, MA. Homozygotes (cPLA 2 α -/-) were interbred in our facility, and their genotypes were regularly confirmed by polymerase chain reaction analysis. Wild type (WT) male BALB/c mice (cPLA 2 α +/+ ) used in this study were purchased from Jackson Laboratory (Bar Harbor, ME). We used littermates initially and found no difference in the action of Ang II in littermates and those mice purchased from Jackson Labs. All animals were 20-30g and approximately 10 weeks of age at the beginning of the experiment.
Ang II-induced hypertension in cPLA 2 α +/+ and cPLA 2 α -/-mice Mice were anesthetized with 1.5% isoflurane to implant micro-osmotic pumps (Alzet®, Cupertino, CA; model 1002), subcutaneously, to infuse Ang II (700 ng/kg/min) or saline for 13 days and systolic blood pressure (SBP) was measured on days 0 (prior to implantation), 3,7,10 and 13 by the noninvasive tail cuff method (Kent Scientific, Torrington, CT; model XBP 1000). Prior to implanting the pumps, mice were acclimated twice to the BP measuring device, with 5 days between measurements.
During these measurements, we noticed an anomaly in these mice. Frequent measurements resulted in mice not being able to attain consistent optimum temperature and so the transducers often failed to sense blood flow to the tails. This made it difficult to measure SBP every third day. We thus measured SBP in two groups of animals after Ang II infusion or vehicle, one in which SBP was measured on days 0, 3 and 10, and in another group on days 0, 7 and 13. This allowed us to obtain consistent measurements of SBP.
These measurements were also confirmed by implanting radio telemetry device (PA-C10, Data Sciences International) in mice. 2 Briefly, mice were anesthetized with 1.5% isoflurane, their core body temperature was maintained by placing them on an heated platform. The catheter of the radio telemetric device was implanted in the thoracic aorta via the left common carotid artery and the device was placed in a subcutaneous pocket on the right flank. The incision was sutured and analgesia (carprofen: 5mg/kg, sc) was administered. The mice were allowed to recover for a week. Systolic, diastolic, mean arterial BP and heart rate was recorded every third day, in the morning, every 10 secs for approximately 1 hr and average values of all data points were calculated.
The power spectral analysis of the data obtained on day 13 of Ang II infusion in cPLA 2  +/+ and cPLA 2  -/-mice was performed to determine arterial pressure and heart rate viability (HRV) with sampling rate of 500 Hz using Dataquest ART software Ver.4.33 (DSI). Low-frequency (LF, 0.1-1 Hz) oscillations of heart rate, which is modulated by sympathetic outflow, and high-frequency (HF, 1-3 Hz) oscillations of heart rate which is modulated by both sympathetic and parasympathetic outflow, were determined. The ratio of LF:HF HRV which reflects sympathetic cardiovascular modulation was determined.
In another series of experiments, cPLA 2 α +/+ mice were infused with Ang II and injected i.p with inhibitor of arachidonic acid metabolism, 5,8,11,14-eicosatetraynoic acid (ETYA) (50 mg/kg/3day) (BML-ET004-0020, Enzo Lifesciences, NY). SBP was measured every third day by tail cuff method.
At the end of the experiment, mice were euthanized with a cocktail of ketamine (100 mg/kg), xylazine (10mg/kg), and acepromazine (3mg/kg) i.p., and their tissues were harvested.
Echocardiography
In another series of experiments, on the 12 th day of the study, mice were anesthetized with 1.5% isoflurane, core body temperature was maintained at 37°C, and heart rate and respiration were continuously monitored with a pulse oximeter. Echocardiography was performed as described 3 by using the Vevo 2100 (VisualSonics, Inc., Toronto, Canada). Briefly, M-mode and B-mode images in the parasternal long-axis and the left ventricular (LV) short-axis views at the midpapillary level were taken. Measurements were averaged from three consecutive beats. M-mode images were used to calculate various parameters of cardiac function including ejection fraction (EF), fractional shortening (FS), stroke volume (SV), cardiac output (CO), and LV mass.
Immunohistochemistry
Immunohistochemical analysis for α-smooth muscle actin (α-SMA) and transforming growth factor β (TGF-β) was performed to determine the extent of interstitial fibrosis as previously described. 4 Tissue sections were also processed for infiltration of CD3 + T lymphocytes and F4/80 + monocyte/macrophage. The hearts and thoracic aortas were dissected free and placed in Optimal Cutting Temperature (OCT) compound (Sakura Finetek USA, Inc., Torrance, CA). Serial transverse cryosections (8-µm thick) were cut at -20°C with a Leica Cryostat CM1850 (Leica Microsystems, Inc., IL). For α-SMA and TGF-β staining, sections were fixed in formalin for 10 min followed by three washes in PBS to remove the mounting medium, after which they were allowed to incubate in 0.3% hydrogen peroxide for 10 min to block endogenous peroxidase activity. The sections were then rinsed once in PBS and blocked in 5% BSA for 30 min. Sections were incubated with their respective primary antibodies overnight at 4°C. All antibodies were diluted in background reducing diluent (Cat #S3022, Dako, CA). Next day, sections were washed three times in PBS and incubated with anti-mouse IgG peroxidaseconjugated secondary antibody for 1 h, washed three times in PBS, and incubated in diaminobenzidine (Cat #D4293, Sigma Aldrich) that was prepared according to manufacturer's instructions, and the tissue sections were then washed with deionized distilled water (ddw). For staining CD3
+ and F4/80 + cells, tissue sections were fixed in cold acetone after which they were allowed to air dry 5-10 min to facilitate complete removal of acetone (sections should appear opaque white). Sections were then washed, followed by the steps described above (Table S1 contains detailed conditions). All sections were counterstained with hematoxylin, dehydrated, mounted, and viewed with an Olympus ® inverted system microscope (Olympus America, Inc., model BX41) and photographed with a SPOT ™ Insight ™ digital camera (Diagnostic Instruments, Inc., model Insight 2MP Firewire).
Collagen accumulation
Masson's trichrome staining (Cat #HT15-1KT, Sigma Aldrich) for collagen accumulation was performed on the heart sections according to manufacturer's instructions with some modifications. Briefly, slides were prefixed in 10% formalin for 20 min followed by fixation in Bouin's reagent overnight at room temperature. Next day, slides were washed in running tap water to drain the yellow stain from Bouin's reagent completely followed by washing in ddw. Weigert's iron hemotoxylin solution (Cat# HT1079, Sigma Aldrich according to vendor's instructions) was applied on the sections for 5 min, and excess stain was removed by rinsing under tap water followed by rinsing with ddw. Slides were then incubated with Scarlet-Fuschin for 5 min, then washed again with tap water followed by washing in ddw. 1:1:2 volume of phosphotungstic acid, phosphomolybdic acid, and ddw was applied on the slide for 10 min. The solution from the slides was drained on a paper towel and then incubated with analine blue for 7 min, then washed with ddw. Tissue sections were then differentiated in 1% glacial acetic acid for 30 sec and then washed twice in ddw followed by dehydration in increasing strengths of alcohol and clearing in xylene after which slides were mounted using permount.
Measurement of vascular function
Vascular reactivity: Following anesthesia, the thoracic aortas were quickly dissected free and cleaned of surrounding tissue, and approximately 2-mm rings were mounted in a wire myograph system (Danish Myo Technology, Aarhus, Denmark; model 610M) as previously described. 5 Vessels were continuously bathed in Krebs buffer (composition in mmol/L: 118 NaCl, 4.7 KCl, 25 NaHCO 3 , 1.2 MgSO 4 , 1.2 KH 2 PO 4 , 11.1 glucose, 2.5 CaCl 2 .2H 2 O) at 37°C, which was gassed with 95% O 2 and 5% CO 2 to maintain pH 7.4. An initial tension of 9 mN was placed on the vessels and allowed to equilibrate for approximately 30 min. To confirm the viability of the vessels, they were initially tested for constriction to 60 mM KCl and then washed three times with fresh Krebs buffer. Cumulative concentration response curves to phenylephrine (PE) and endothelin-1 (ET-1) were obtained and responses measured as force of contraction (mN).
Endothelium-dependent and -independent vasodilation: Endothelial function was examined 5 by constricting the vessels with the concentration of PE that evoked a maximal response followed by adding increasing concentrations of acetylcholine (ACh). Changes in the response of vessels to ACh were measured and presented as a percentage of the PE-induced constriction. Endothelium-independent vasodilation was studied by constricting the vessels with the concentration of PE that evoked a maximal response followed by adding increasing concentrations of sodium nitroprusside (SNP). Changes in the response of vessels to SNP were measured and presented as a percentage of the PE-induced constriction.
Measurement of media:lumen ratio: Aortic sections were stained with hematoxylin and eosin and then were viewed using an Olympus ® inverted system microscope (Olympus America, Inc., Melville, NY; model IX50) and photographed with an Olympus ® digital camera (Olympus America,Inc.; model DP71). Images were analyzed using ImageJ 1.42 (http://rsb.info.nih.gov/nih-image; National Institutes of Health).
Measurement of Oxidative Stress
NADPH oxidase activity: NADPH oxidase activity was determined in heart homogenates by measuring lucigenin (N,N′-dimethyl-9,9′-biacridinium dinitrate)-enhanced chemiluminescence, as described previously 6 , with some modifications. Following anesthesia, a transcardial PBS perfusion was performed; hearts were harvested and snap-frozen in liquid N 2 and stored at -80°C until use. Tissues were homogenized and sonicated in lysis buffer containing protease inhibitors (20 mmol/L phosphate buffer, 1 mmol/L EGTA, 10 µg/ml aprotinin, 0.5 µg/ml leupeptin, 0.7 µg/ml pepstatin, 0.5 mmol/L phenylmethylsulphonylfluoride, and 150 mmol/L sucrose). Samples were then centrifuged at 3,000 g for 10 min at 4°C, and supernatants were kept on ice until use. Protein content in the samples was determined by the Bradford method, and equal amounts of protein were combined 1:1 with a reaction mixture containing 5 µmol/L lucigenin (final concentration) and 100 µmol/L NADPH (final concentration). Luminescence was measured every minute for 10 min with a luminometer (Turner Designs, Sunny Vale, CA; model TD-20/20). Lysis buffer was used as a blank and subtracted from each reading and activity expressed as arbitrary units.
Measurement of vascular reactive oxygen species production: To measure vascular reactive oxygen species productions, sections of thoracic aorta and heart were exposed to dihydroethidium (DHE) (Cat #D-2310, Life Technologies, NY) following the previously described and validated method. 7 Aortic sections were incubated in PBS for 30 min at 37°C and then encircled with a hydrophobic pen. DHE (2 µM for aorta, 5 µM for heart) was topically applied. Sections were further incubated at 37°C in a light-protected humidified chamber for 30 min. Sections were then rinsed in PBS, and fluorescence was detected with a 585-nm filter and an Olympus ® inverted system microscope (Olympus America, Inc.; model DP71) and measured as fluorescence of 2-hydroxyethidium (2-OHE). Images were photographed with an Olympus ® digital camera (Olympus America, Inc., model DP71) and analyzed using ImageJ 1.42 (http://rsb.info.nih.gov/nih-image; National Institutes of Health).
Urinary levels of Eicosanoids
24hr urine sample was collected by placing the mice in metabolic cages. PGE2 is rapidly converted in vivo to its 13,14-dihydro-15-keto metabolite that further under goes degradation to PGA products , thus we measured the concentration of its metabolites using a Prostaglandin E Metabolite EIA Kit ELISA kit (Cayman Cat# 514531) as per manufacturer's instructions. This kit enables the conversion of 13,14-dihydro-15-keto PGA2 and 13,14-dihydro-15-keto PGE2 to a single, stable derivative that can be quantified. TXB2 levels were measured using an ELISA kits (Cayman Cat # 501020) 20-HETE levels were quantified by LC/MS using a previously described method. 8 For solid phase extraction, urine samples were thawed on ice, 150 µL of urine, 5 µL of internal standard and 50 µL of ethanol mixture was sonicated for 10 seconds. The samples were applied to BondElute Solid Phase Extraction columns (#12102052, Agilent Tech, Santa Clara, CA). Columns were washed with 5 ml of ultrapure water five times, followed by elution with 6 ml ethyl acetate. Upper phase was collected into siliconized glass tube. The elution process was repeated once more. Ethyl acetate was evaporated under nitrogen. Samples were kindly analyzed by LC/MS by Dr. Sandra L. Pfister, Department of Pharmacology, Medical College of Wisconsin, Milwaukee, WI).
Western blot analysis
Heart samples were homogenized in lysis buffer, and protein content was determined by the Bradford method. 50 µg of proteins were loaded and resolved on 8% or 12% SDSpolyacrylamide gels and processed for Western blot analysis as described. 9 Blots were probed with different primary and corresponding secondary antibodies (Table S1 contains detailed conditions). Intensity of the bands was measured with ImageJ 1.42 software.
Real-time PCR analysis
Total RNA was extracted with TRIzol reagent (Invitrogen) according to the manufacturer's protocol. 1µg of purified RNA was reverse transcribed using SuperScript TM III First Strand synthesis system (Invitrogen). Transcription level was normalized to cycophilin D. Primers were designed (Table S2) . The values were calculated by 2 -ΔΔCt method.
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Statistical analysis
Data were analyzed by repeated measures two-way analysis of variance or one-way analysis of variance followed by Turkey's multiple comparison tests or Student's t-test. The values of a minimum of three different experiments are expressed as the mean ± SEM. P values < 0.05 were considered statistically significant. TGC GGA TGT GG  ACG GTC GCT CTC CTA TAG TAT G  Xbp1  AAG AAA GCC CGG ATG AGC  AGC GTG TTC TTA ACT CCT GG  CHOP  TGT TGA AGA TGA GCG GGT G  AGG TTC TGC TTT CAG GTG TG  GRP78 AGT TGA TAT TGG AGG TGG GC CAT TGA AGT AAG CTG GTA CAG TAA C
Figure S1
A-1 Figure S1 . Tracings of systolic blood pressure (SBP), diastolic blood pressure (DBP) and mean arterial pressure (MAP) from individual experiments obtained during Ang II infusion, heart rate, ratio of low frequency (LF): high frequency (HF) of heart rate variability, and cPLA 2 activity. Ang II-infusion increased BP measured by radio telemetry, in cPLA 2 α +/+ (A-1), but not in cPLA 2 α -/-mice (A-2), did not alter heart rate in both phenotypes (B), increased the ratio of low LF:HF heart rate variability, index of sympathetic outflow modulation in cPLA 2 α +/+ but not cPLA 2 α -/-mice determined by spectral analysis (C), and increased cardiac PLA 2 activity in cPLA 2 α +/+ mice measured by its phosphorylation; the expression of cPLA 2 protein was absent in cPLA 2 
